Scientia Advisors in the News

---

Publications

---

Press Releases

---

Events

---

Luminary Insights

---

Media Contact

---

Webinars

How a New Set of Players is Changing Personalized Medicine

Topic:

Personalized medicine is becoming increasingly complicated as new stakeholders enter the arena, changing the dynamics for the entire industry. Drugmakers are scrambling to find the right partners to develop diagnostics. Laboratory-developed tests are undergoing regulatory scrutiny. And third-party payers want more evidence of treatments that can deliver for their customers.

But what is the future of targeted treatments and diagnostics? What does the regulatory landscape look like? How will the increasing emphasis on health outcomes change the equation? Learn needed insights and how the emergence of non-traditional players will alter the way business will be done with Harry Glorikian, managing partner at Scientia Advisers and a former biotech executive.

Attend to understand:

• What it means when pharmacy benefit managers use genetic testing
• The value of personalized medicine in the health care reform era
• The challenges for co-developing drugs and diagnostics
• How the FDA will handle laboratory developed tests
• Potential impact of next generation sequencing on personalized medicine
• Influence of healthcare IT on personalized medicine

Session speakers:

• Harry Glorikian, Partner at Scientia Advisors - Expert Presenter
• Ed Silverman, Editor at Pharmalot; Editor-at-Large for Med Ad News and R&D Directions - Moderator

Who should attend?

Professionals with responsibilities in:

• Clinical Operations and Clinical Research
• Regulatory Affairs
• Medical Affairs
• Health Economics and Outcomes
• Reimbursement
• Government Affairs and Policy
• Business Strategy and Development
• Drug Discovery
• Clinical Pharmacology
• Biomarkers